MedTrace Logo

Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers

NCT03903549 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2023-01-11

No results posted yet for this study

Summary

This study investigates the initial safety profile of \[18F\]P17-059 in healthy volunteers including dosimetry determination, and compares regional brain uptake and kinetics of \[18F\]P17-059 in Parkinson's disease patients with regional brain uptake and kinetics of \[18F\]P17-059 in healthy volunteers.

Conditions

  • Parkinson Disease

Interventions

DRUG

[18F]P17-059

Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning

Sponsors & Collaborators

  • Five Eleven Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Martin Pomper, MD PhD · Johns Hopkins Medical School

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2022-12-19
Completion
2022-12-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03903549 on ClinicalTrials.gov